Alterity Therapeutics (FRA:PBN) Cash Flow for Dividends: €0.00 Mil (TTM As of Dec. 2025)


FRA:PBN Alterity Therapeutics Ltd FRA:PBN
26 GF Score
Price €0.33
View Full Analysis

What is Alterity Therapeutics Cash Flow for Dividends?

Alterity Therapeutics FRA:PBN -3.55% 26 Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:PBN with a GF Score™ of 26/100.

Alterity Therapeutics's cash flow for dividends for the three months ended in Dec. 2025 was €0.00 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Alterity Therapeutics Cash Flow for Dividends Related Terms

Alterity Therapeutics Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Cash Flow for Dividends Chart

Alterity Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Alterity Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PBN
26GF Score
Alterity Therapeutics Ltd FRA:PBN
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0.00 Mil mean?
Alterity Therapeutics (FRA:PBN) has a Cash Flow for Dividends of €0.00 Mil as of Dec. 2025. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Alterity Therapeutics and its competitors.
Is Alterity Therapeutics' Cash Flow for Dividends too high?
Alterity Therapeutics' current Cash Flow for Dividends is €0.00 Mil. Overall, Alterity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Alterity Therapeutics' Cash Flow for Dividends compare to VRTX and REGN?
Alterity Therapeutics' Cash Flow for Dividends of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Alterity Therapeutics and its competitors. Alterity Therapeutics's current Cash Flow for Dividends is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alterity Therapeutics stock overvalued right now?
Alterity Therapeutics (FRA:PBN) has a current Cash Flow for Dividends of €0.00 Mil. The current Cash Flow for Dividends is €0.00 Mil. Alterity Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Alterity Therapeutics (FRA:PBN), the current Cash Flow for Dividends is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAATH:Australia
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
26GF Score

Get the complete analysis for FRA:PBN

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price